Abstract
Primary signet-ring cell carcinoma (SRCC) of the urinary bladder, a variant of adenocarcinoma, is exceedingly rare and as a result no gold standard exists for its management. We report a case of primary SRCC of the bladder with recurrent metastases; we utilized an innovative diagnostic approach and the patient exhibited a treatment response to palliative FOLFOX-6 chemotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | E204-E207 |
Journal | Journal of the Canadian Urological Association |
Volume | 9 |
Issue number | 3-4APRIL |
DOIs | |
State | Published - Apr 13 2015 |
Keywords
- Bladder cancer
- FOLFOX-6
- Metastatic
- Next generation sequencing
- Signet-ring cell carcinoma
ASJC Scopus subject areas
- Oncology
- Urology